ReP USP - Resultado da busca

Artigo de periodico
Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score (2022)
Burtness, Barbara; Rischin, Danny; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Brana, Irene; Baste, Neus; Neupane, Prakash
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS DE CABEÇA E PESCOÇO, QUIMIOTERAPIA, CARCINOMA DE CÉLULAS ESCAMOSAS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, v. 40, n. 21, p. 2321-2334, 2022Tradução . . Disponível em: https://doi.org/10.1200/JCO.21.02198. Acesso em: 19 out. 2024.
APA
Burtness, B., Rischin, D., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, 40( 21), 2321-2334. doi:10.1200/JCO.21.02198
NLM
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.21.02198
Vancouver
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.21.02198
Artigo de periodico
Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR (2020)
Fatobene, Giancarlo; Rocha, Vanderson Geraldo ; Martin, Andrew St; Hamadani, Mehdi; Robinson, Stephen; Bashey, Asad; Boumendil, Ariane; Brunstein, Claudio; Castagna, Luca; Dominietto, Alida
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: LEUCEMIA, TRANSPLANTE DE MEDULA ÓSSEA, SOBREVIDA, LINFOMA, PESQUISA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FATOBENE, Giancarlo et al. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. Journal of clinical oncology, v. 38, n. 14, p. 1518-+, 2020Tradução . . Disponível em: https://doi.org/10.1200/JCO.19.02408. Acesso em: 19 out. 2024.
APA
Fatobene, G., Rocha, V. G., Martin, A. S., Hamadani, M., Robinson, S., Bashey, A., et al. (2020). Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. Journal of clinical oncology, 38( 14), 1518-+. doi:10.1200/JCO.19.02408
NLM
Fatobene G, Rocha VG, Martin AS, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR [Internet]. Journal of clinical oncology. 2020 ; 38( 14): 1518-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.19.02408
Vancouver
Fatobene G, Rocha VG, Martin AS, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR [Internet]. Journal of clinical oncology. 2020 ; 38( 14): 1518-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.19.02408
Artigo de periodico
Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma (2019)
O'connor, Owen A; Ozcan, Muhit; Jacobsen, Eric D; Roncero, Josep M; Trotman, Judith; Demeter, Judit; Masszi, Tamas; Pereira, Juliana; Ramchandren, Radhakrishnan; Beaven, Anne
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: LINFOMA, LINFÓCITOS T, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
O'CONNOR, Owen A et al. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma. Journal of clinical oncology, v. 37, n. 8, p. 613-+, 2019Tradução . . Disponível em: https://doi.org/10.1200/JCO.18.00899. Acesso em: 19 out. 2024.
APA
O'connor, O. A., Ozcan, M., Jacobsen, E. D., Roncero, J. M., Trotman, J., Demeter, J., et al. (2019). Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma. Journal of clinical oncology, 37( 8), 613-+. doi:10.1200/JCO.18.00899
NLM
O'connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma [Internet]. Journal of clinical oncology. 2019 ; 37( 8): 613-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.18.00899
Vancouver
O'connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma [Internet]. Journal of clinical oncology. 2019 ; 37( 8): 613-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.18.00899
Artigo de periodico
First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial (2018)
Rimawi, Mothaffar; Ferrero, Jean-Marc; Haba-rodriguez, Juan de la; Poole, Christopher; Placido, Sabino De; Osborne, C. Kent; Hegg, Roberto; Easton, Valerie; Wohlfarth, Christine; Arpino, Grazia
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, INIBIDORES DE ENZIMAS, RECEPTORES DE ESTEROIDES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIMAWI, Mothaffar et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, v. 36, n. 28, p. 2826-2835, 2018Tradução . . Disponível em: https://doi.org/10.1200/JCO.2017.76.7863. Acesso em: 19 out. 2024.
APA
Rimawi, M., Ferrero, J. -M., Haba-rodriguez, J. de la, Poole, C., Placido, S. D., Osborne, C. K., et al. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, 36( 28), 2826-2835. doi:10.1200/JCO.2017.76.7863
NLM
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863
Vancouver
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863
Trabalho de evento-resumo periodico
Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer (2016)
Pereira, Guilherme Luiz Stelko; Fonseca, Leonardo Gomes da; Ramos, Marcus Fernando Kodama Pertille; Ribeiro Júnior, Ulysses; Pereira, Gabriel; Pereira, Marina Alessandra; Mello, Evandro Sobroza de; Sabbaga, Jorge; Hoff, Paulo Marcelo Gehm
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS GÁSTRICAS, METÁSTASE NEOPLÁSICA, PROCEDIMENTOS CIRÚRGICOS DO SISTEMA DIGESTÓRIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA, Guilherme Luiz Stelko et al. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer. Journal of clinical oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meetinglibrary.asco.org/content/159941-173. Acesso em: 19 out. 2024. , 2016
APA
Pereira, G. L. S., Fonseca, L. G. da, Ramos, M. F. K. P., Ribeiro Júnior, U., Pereira, G., Pereira, M. A., et al. (2016). Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer. Journal of clinical oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meetinglibrary.asco.org/content/159941-173
NLM
Pereira GLS, Fonseca LG da, Ramos MFKP, Ribeiro Júnior U, Pereira G, Pereira MA, Mello ES de, Sabbaga J, Hoff PMG. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer [Internet]. Journal of clinical oncology. 2016 ; 34( 04): su01.[citado 2024 out. 19 ] Available from: http://meetinglibrary.asco.org/content/159941-173
Vancouver
Pereira GLS, Fonseca LG da, Ramos MFKP, Ribeiro Júnior U, Pereira G, Pereira MA, Mello ES de, Sabbaga J, Hoff PMG. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer [Internet]. Journal of clinical oncology. 2016 ; 34( 04): su01.[citado 2024 out. 19 ] Available from: http://meetinglibrary.asco.org/content/159941-173
Artigo de periodico
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular Era: a retrospective multicohort analysis (2016)
Ramaswamy, Vijay; Hielscher, Thomas; Mack, Stephen C.; Lassaletta, Alvaro; Lin, Tong; Pajtler, Kristian; Jones, David T. W; Luu, Betty; Cavalli, Florence M. G.; Aldape, Kenneth; Remke, Marc; Mynarek, Martin; Rutkowski, Stefan; Gururangan, Sridharan; McLendon, Roger E.; Lipp, Eric S.; Dunham, Cristopher; Hukin, Juliette; Eisenstat, David D.; Fulton, Dorcas; Landeghem, Frank K. H. van; Santi, Mariarita; Veelen, Marie-Lise C. van; Meir, Erwin G. Van; Osuka, Satoru; Fan, Xing; Muraszko, Karin Muraszko; Tirapelli, Daniela Pretti da Cunha; Shinjo, Sueli Mieko Oba; Marie, Suely Kazue Nagahashi; Carlotti Júnior, Carlos Gilberto; Yeoun, Ji; Rao, Amulya A. Nageswara; Giannini, Caterina; Faria, Claudia C.; Nunes, Sofia; Mora, Jaume; Hamilton, Ronald L.; Hauser, Peter; Jabado, Nada; Petrecca, Kevin; Jung, Shin; Massimi, Luca; Zollo, Massimo; Cinalli, Giuseppe; Bognár, László; Klekner, Almos; Hortobágyi, Tibor; Leary, Sarah; Ermoian, Ralph P.; Olson, James M.; Leonard, Jeffrey R.; Gardner, Corrine; Grajkowska, Wieslawa; Chambless, Lola B.; Cain, Jason; Eberhart, Charles; Massimino, Maura; Giangaspero, Felice; Buttarelli, Francesca R.; Packer, Roger J.; Emery, Lyndsey; Yong, William H.; Soto, Horacio; Liau, Linda M.; Everson, Richard; Grossbach, Andrew; Shalaby, Tarek; Grotzer, Michael; Karajannis, Mathias A.; Zagzag, David; Wheeler, Helen; Hoff, Katja on; Alonso, Marta M.; Tuñon, Teresa; Schüller, Ulrich; Zitterbart, Karel; Sterba, Jaroslav; Chan, Jennifer A.; Guzman, Miguel; Elbabaa, Samer K.; Colman, Howard; Dhall, Girish; Fisher, Paul G.; Fouladi, Marvan; Gajjar, Amar; Goldman, Stewart; Hwang, Eugene; Kool, Marcel; Ladha, Harshad; Bolanos, Elizabeth Vera; Wani, Khalida; Lieberman, Frank; Mikkelsen, Tom; Omuro, Antonio M.; Pollack, Ian F.; Prados, Michael; Robins, H. Ian; Soffietti, Riccardo; Wu, Jing; Metellus, Philipe; Tabori, Uri; Bartels, Ute; Bouffet, Eric; Hawkins, Cynthia E.; Rutka, James T.; Dirks, Peter; Pfister, Stefan M.; Merchant, Thomas E.; Gilbert, Mark R.; Armostrong, Terri S.; Korshunov, Andrey; Ellison, David W.; Taylor, Michael D.
Fonte: Journal of clinical oncology. Unidades: FMRP, FM
Assuntos: NEOPLASIAS DE CABEÇA E PESCOÇO, PROGNÓSTICO, ESTUDOS DE COORTES, NEOPLASIAS DA BASE DO CRÂNIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAMASWAMY, Vijay et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular Era: a retrospective multicohort analysis. Journal of clinical oncology, v. 34, n. 21, p. 2468-2477, 2016Tradução . . Disponível em: http://ascopubs.org/doi/pdf/10.1200/JCO.2015.65.7825. Acesso em: 19 out. 2024.
APA
Ramaswamy, V., Hielscher, T., Mack, S. C., Lassaletta, A., Lin, T., Pajtler, K., et al. (2016). Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular Era: a retrospective multicohort analysis. Journal of clinical oncology, 34( 21), 2468-2477. doi:10.1200/JCO.2015.65.7825
NLM
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler K, Jones DTW, Luu B, Cavalli FMG, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, Landeghem FKH van, Santi M, Veelen M-LC van, Meir EGV, Osuka S, Fan X, Muraszko KM, Tirapelli DP da C, Shinjo SMO, Marie SKN, Carlotti Júnior CG, Yeoun J, Rao AAN, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska W, Chambless LB, Cain J, Eberhart C, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, Hoff K on, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Bolanos EV, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armostrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular Era: a retrospective multicohort analysis [Internet]. Journal of clinical oncology. 2016 ; 34( 21): 2468-2477.[citado 2024 out. 19 ] Available from: http://ascopubs.org/doi/pdf/10.1200/JCO.2015.65.7825
Vancouver
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler K, Jones DTW, Luu B, Cavalli FMG, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, Landeghem FKH van, Santi M, Veelen M-LC van, Meir EGV, Osuka S, Fan X, Muraszko KM, Tirapelli DP da C, Shinjo SMO, Marie SKN, Carlotti Júnior CG, Yeoun J, Rao AAN, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska W, Chambless LB, Cain J, Eberhart C, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, Hoff K on, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Bolanos EV, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armostrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular Era: a retrospective multicohort analysis [Internet]. Journal of clinical oncology. 2016 ; 34( 21): 2468-2477.[citado 2024 out. 19 ] Available from: http://ascopubs.org/doi/pdf/10.1200/JCO.2015.65.7825
Artigo de periodico
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer (2012)
Baselga, José; Segalla, José Getúlio Martins; Roché, Henri; Giglio, Auro del; Pinczowski, Hélio; Ciruelos, Eva M.; Cabral Filho, Sebastião; Gómez, Patricia; Van Eyll, Brigitte; Bermejo, Begoña; Llombart, Antonio; Garicochea, Bernardo; Durán, Miguel Ángel Climent; Hoff, Paulo Marcelo Gehm; Espié, Marc; Moraes, Andre Augusto Junior Gemeinder de; Ribeiro, Ronaldo Albuquerque; Mathias, Clarissa; Gil Gil, Miguel; Ojeda, Belén; Morales, Josefa; Ro, Sunhee Kwon; Li, Shell; Costa, Frederico
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS (DIETOTERAPIA), NEOPLASIAS CEREBRAIS (SECUNDÁRIO), ADENOCARCINOMA, QUIMIOTERAPIA ADJUVANTE, METÁSTASE NEOPLÁSICA, FATORES DE CRESCIMENTO, ANTICORPOS MONOCLONAIS, ENDOTÉLIO VASCULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASELGA, José et al. Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of clinical oncology, v. 30, n. 13, p. 1484-1491, 2012Tradução . . Disponível em: http://jco.ascopubs.org/content/30/13/1484.full.pdf+html. Acesso em: 19 out. 2024.
APA
Baselga, J., Segalla, J. G. M., Roché, H., Giglio, A. del, Pinczowski, H., Ciruelos, E. M., et al. (2012). Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of clinical oncology, 30( 13), 1484-1491. doi:10.1200/JCO.2011.36.7771
NLM
Baselga J, Segalla JGM, Roché H, Giglio A del, Pinczowski H, Ciruelos EM, Cabral Filho S, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁC, Hoff PMG, Espié M, Moraes AAJG de, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Ro SK, Li S, Costa F. Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer [Internet]. Journal of clinical oncology. 2012 ; 30( 13): 1484-1491.[citado 2024 out. 19 ] Available from: http://jco.ascopubs.org/content/30/13/1484.full.pdf+html
Vancouver
Baselga J, Segalla JGM, Roché H, Giglio A del, Pinczowski H, Ciruelos EM, Cabral Filho S, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁC, Hoff PMG, Espié M, Moraes AAJG de, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Ro SK, Li S, Costa F. Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer [Internet]. Journal of clinical oncology. 2012 ; 30( 13): 1484-1491.[citado 2024 out. 19 ] Available from: http://jco.ascopubs.org/content/30/13/1484.full.pdf+html
Artigo de periodico
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury (2011)
Overman, Michael J; Maru, Dipen M; Charnsangavej, Chusilp; Loyer, Evelyn M; Wang, Huamin; Oathak, Priyanka; Eng, Cathy; Hoff, Paulo Marcelo Gehm; Vauthey, Jean-Nicolas; Wolff, Robert a; Kopetz, Scott
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: BIOMARCADORES, FÍGADO (LESÕES;FISIOPATOLOGIA), HEPATOPATIAS (FISIOPATOLOGIA;ETIOLOGIA;COMPLICAÇÕES), MEDICAMENTO (EFEITOS ADVERSOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OVERMAN, Michael J et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, v. 28, n. 14, p. 2549-2555, 2011Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.27.5701. Acesso em: 19 out. 2024.
APA
Overman, M. J., Maru, D. M., Charnsangavej, C., Loyer, E. M., Wang, H., Oathak, P., et al. (2011). Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, 28( 14), 2549-2555. doi:10.1200/JCO.2009.27.5701
NLM
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701
Vancouver
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Agência de fomento